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Abstract
Salmonella enterica is an important enteric pathogen and its various serovars are involved in causing both systemic and
intestinal diseases in humans and domestic animals. The emergence of multidrug-resistant strains of Salmonella leading to
increased morbidity and mortality has further complicated its management. Live attenuated vaccines have been proven
superior over killed or subunit vaccines due to their ability to induce protective immunity. Of the various strategies used for
the generation of live attenuated vaccine strains, focus has gradually shifted towards manipulation of virulence regulator
genes. Hfq is a RNA chaperon which mediates the binding of small RNAs to the mRNA and assists in post-transcriptional
gene regulation in bacteria. In this study, we evaluated the efficacy of the Salmonella Typhimurium Dhfq strain as a
candidate for live oral vaccine in murine model of typhoid fever. Salmonella hfq deletion mutant is highly attenuated in cell
culture and animal model implying a significant role of Hfq in bacterial virulence. Oral immunization with the Salmonella hfq
deletion mutant efficiently protects mice against subsequent oral challenge with virulent strain of Salmonella Typhimurium.
Moreover, protection was induced upon both multiple as well as single dose of immunizations. The vaccine strain appears
to be safe for use in pregnant mice and the protection is mediated by the increase in the number of CD4
+ T lymphocytes
upon vaccination. The levels of serum IgG and secretory-IgA in intestinal washes specific to lipopolysaccharide and outer
membrane protein were significantly increased upon vaccination. Furthermore, hfq deletion mutant showed enhanced
antigen presentation by dendritic cells compared to the wild type strain. Taken together, the studies in murine
immunization model suggest that the Salmonella hfq deletion mutant can be a novel live oral vaccine candidate.
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Introduction
Salmonellae are Gram-negative, facultative intracellular patho-
gens, causing variety of diseases in multiple hosts with different
disease outcome. The genus Salmonella is composed of two distinct
species: Salmonella bongori, a commensal of cold-blooded animals
and Salmonella enterica. Salmonella enterica has 6 subspecies, and each
subspecies have associated serovars that differ by antigenic
specificity and comprises of more than 2500 serovars [1].
Serotypes within subspecies I (S. enterica subsp. enterica) are
responsible for the vast majority of the Salmonella infections in
warm-blooded animals [2]. These serotypes differ widely in a
variety of features, most notably in their host range, severity and
type of disease they typically cause. S. enterica serovar Typhimur-
ium is an important cause of food poisoning and human
gastroenteritis and has added significance as a model of human
typhoid fever in mice. S.Typhimurium infection is often fatal if
remained untreated in immuno-compromised patients [2,3].
S. enterica serovar Typhi (S.Typhi) and S. enterica serovar
Paratyphi (S.Paratyphi) cause typhoid and paratyphoid fever in
humans; mostly in developing and under developed countries.
They still remain a significant public health problem in many parts
of the world. Annual global burden of typhoid is about 21.2
million cases and death rate of ,2.2 lakh individuals per year
worldwide, whereas paratyphoid accounts to 5.4 million cases per
year globally [4,5]. WHO reports that in some developing
countries of Asia and Africa, the annual incidence of typhoid
fever may reach 1% with case fatality rates as high as 10% [6].
Vaccination has been practiced for many years and it is one of
the most effective methods of controlling infectious diseases like
typhoid. Currently two licensed vaccines against Salmonella are in
use globally, Vi polysaccharide vaccine and Ty21a live attenuated
vaccine [7]. Typhim Vi is the purified Vi antigen from S. Typhi
and vaccination with Typhim Vi provides 55–75% protection in
one single dose [8]. The other licensed typhoid vaccine is Vivotif
Berna which is an attenuated live Salmonella Typhi Ty21a strain,
generated by chemical mutagenesis of parental virulent strain of
Salmonella Typhi Ty21 [9]. Vivotif is highly immunogenic, but an
important practical shortcoming is its three to four dosage
requirement of 2–6610
9 CFU every alternate day [10]. Most of
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by deleting essential genes of the metabolic pathway, pathogenicity
islands or global regulators. Salmonella harboring mutations in SPI-
2 [11], aroA [12,13], hrtA [14], phoP [15], rpoS [16], rfaH [17],
dam [18,19,20], trxA [21], FoF1 ATPase [22] have been tested as
vaccine candidates in animal models. The major challenge in the
development of live attenuated Salmonella vaccines is generating a
safe yet immunogenic vaccine strain.
Hfq is a RNA chaperon which plays a vital role in regulating the
stability as well as the translational activity of several mRNAs
through small non-coding RNA. Initially, Hfq was identified in E.
coli as a host factor essential for replication of bacteriophage Qb
[23]. Later it was found that the E.coli hfq deletion mutant exhibits
pleiotropic phenotypes that include decreased growth rate, change
in the morphology, altered sensitivity to UV light and oxidants
[24]. It has now been shown that Hfq impedes the translation of
the major stress sigma factor, s
S (RpoS) in the enteric bacteria viz
E.coli and Salmonella [25,26]. Hfq has also emerged as a key player
in mRNA translational control by small non-coding RNAs
(sRNAs) [27]. Studies later demonstrated that Hfq was involved
in Salmonella pathogenesis through its effect on expression and
secretion of virulence factors (in a s
S-independent manner)
resulting in an attenuation of the Salmonella hfq deletion mutant
in cell culture system as well as in murine model [28]. Global
microarray and proteomic analyses of Salmonella Typhimurium
grown aboard the space shuttle mission STS-115 identified Hfq as
the global regulator involved in the response to the space flight
environment as well [29]. Therefore, it becomes evident that Hfq
is a bacterial RNA binding protein having many important
physiological roles.
The aim of the present study is to evaluate the efficacy of
Salmonella enterica serovar Typhimurium lacking hfq gene as a
candidate for live oral vaccine against Salmonella infection in
murine salmonellosis model. The data suggests that the STMDhfq
is able to elicit protective immune responses against oral challenge
with Salmonella virulent strain. Further, the vaccination with
STMDhfq is safe in the pregnant mice. The protective response
elicited by the mutant strain is characterized by an increase in total
CD4
+ T lymphocytes population, serum IgG and intestinal
secretary-IgA antibodies.
Results
Salmonella hfq deletion mutant construction and in vitro
characterization
hfq gene was deleted from Salmonella enterica serovar Typhimur-
ium using the lambda red recombination system [30] and mutants
were confirmed by colony PCR with confirmatory primers against
the sequence flanking the hfq gene (Figure 1A). The same were also
confirmed using primers against the kanamycin cassette (data not
shown). We then compared the growth of the hfq deletion mutant
with that of the STM-WT in rich media (LB) and defined media
(minimal media). While the number of viable bacteria was found
to be same for equal OD of both the cultures, the hfq mutant
reached stationary phase at later time than STM-WT in both LB
as well as in the minimal media (data not shown).
Salmonella encounters two major cells during its course of
pathogenesis namely epithelial cells and macrophage cells which
are the main cells that support the bacterial growth in vivo [31].
Infection of cultured phagocytic and epithelial cells mimics
relevant in vivo host-pathogen interactions, bacterial invasion and
intracellular multiplication. Therefore, we checked the intracellu-
lar replication capacity of the hfq mutant in human epithelial as
well as murine macrophage cell lines. The hfq mutant is highly
defective in its replication capacity (3-5 fold) as compared to that of
the WT in all the cell lines tested except CaCo-2. In CaCo-2 cells,
the mutant is highly attenuated and the fold replication difference
is ,15-fold (Figure 1B). This implies that the hfq mutant is
attenuated in both the macrophage and epithelial cell lines
(Figure 1B).
Attenuation of the Salmonella hfq deletion mutant in
mouse model
Having observed the attenuation of STMDhfq in epithelial as
well as in macrophage cell lines, we decided to investigate the
virulence of the mutant strain in the murine model of typhoid
fever. To analyze the bacterial colonization in different organs,
group of BALB/c mice were infected orally with 10
7 CFU of WT
Salmonella and STMDhfq. As shown in Figure 1C and D, organ
load of the STMDhfq was significantly lower (<100-1000 fold,
p,0.05) when compared to the STM-WT, 4
th day post infection
in spleen, liver and mesenteric lymph nodes. The STMDhfq was
completely cleared by 7
th day post infection unlike the STM-WT.
This suggested that the mutant is severely attenuated and is
efficiently cleared from the different organs of mice.
Complementation of hfq gene restored STMDhfq
virulence
The wild type hfq gene was cloned into pQE60 vector and the
resultant pQE60hfq plasmid was transformed into STMDhfq strain.
The WT, mutant and STMDhfqpQE60hfq were used for
complementation studies in cell lines as well as in murine model.
The complemented strain behaved like the WT in terms of
intracellular replication in both RAW 264.7 and INT-407 cell
lines as well as in animal model (Figure S1 A&B). The bacterial
burden in spleen, liver and mesenteric lymph nodes at single time
point (4
th day) suggests that the tans-complementation with hfq
gene restored the mutant’s virulence (Figure S1 C).
Safety of the Salmonella hfq deletion mutant
To determine the extent of the effect of the hfq deletion on
Salmonella virulence, we determined LD50 values using the
STMDhfq in female BALB/c mice. The LD50 value of the wild-
type was 4610
4 CFU for oral administration. In case of mice
infected with STMDhfq,L D 50 could not be estimated because
mice did not die even after oral inoculation with the maximum
dose of 10
9 CFU/mouse. The mice that survived infection with
the STMDhfq did not show any signs of illness and remained
healthy for the entire duration of the experiment.
Next, we studied the survival of mice, upon infection with the
STM hfq deletion mutant. The infection was carried out by either
oral (10
8) or intraperitoneal route (10
4) and the survival was
monitored for 3 weeks. Infection with the wild type strain through
either route led to an early onset of symptoms in the mice followed
by death within ten days, whereas 100% percent survival was
observed in case of mice infected with STMDhfq through oral
route. However, in intra-peritoneal infection, the percent survival
of mice was found to be 70% in the case of STMDhfq.
(Figure 2A&B). The surviving mice remained healthy up to 7
weeks (monitored for 7 weeks only). The high attenuation of the
STMDhfq mutant given through oral route thus renders it highly
safe for infection in mice.
The high levels of shedding exhibited by Salmonella Typhimur-
ium strains have precluded their development as live Salmonella
vaccines. Therefore, we compared the fecal shedding of the STM-
WT and the vaccine strain STMDhfq in the murine model. As
shown in Figure 2C, the vaccine strain was shed lesser in the feces
hfq and Vaccination
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strain was observed up to 36 h of post administration and no
Salmonella were detected exceeding the time period. No Salmonellae
were recovered from the fecal matter of naive mice. Our results
conclusively demonstrate that the STMDhfq vaccine strain is shed
lesser in the feces.
STMDhfq imparts protection against subsequent
challenge with the virulent Salmonella in mice
A good vaccine candidate should be attenuated, safe, immuno-
genic and should give protection against a lethal challenge with
minimum dose of priming. Having demonstrated that the vaccine
strain is attenuated and safe in the murine Salmonella model, next
we examined the ability of attenuated STMDhfq strain to generate
protective immunity against the virulent Salmonella infection. We
followed the immunization strategy as given in Figure S2. Cohorts
of five mice each were orally primed with the STMDhfq at a dose
of 10
3,1 0
4 or 10
5 bacteria/mouse followed by two booster doses
(day 7 and 14). Control mice received PBS. All the subsequent
steps (challenge, sacrifice) were carried out with a gap of seven
days between them. Seven days after the final booster dose, the
mice were challenged with 10
7 CFU of STM-WT through oral
route for analyzing organ infiltration. For survival assay, mice
were challenged with 10
8 CFU/mouse through oral route. In case
Figure 1. STMDhfq is highly attenuated in vitro and in vivo (A) Generation of STMDhfq by one step gene inactivation. Confirmatory PCR
showing the presence of Kanamycin cassette (1.5 Kb) in STMDhfq. (B) Intracellular replication of STM-WT and STMDhfq strains in INT-407, HT-29,
CaCo-2 and RAW 264.7 cell lines. Cells were infected with the STMDhfq or STM-WT at an MOI of 10. Data shows fold increase from 2 h to 16 h. All the
experiments were done in triplicate. (C&D) Organ loads of STM-WT and STMDhfq. Two groups of mice (5 each) were infected with 10
7 CFU/mouse
orally and sacrificed on day 4 (C) and day 7 (D) of post infection. Bacterial counts in spleen, MLN and liver were shown as CFU/gm.wt with standard
errors. Plots are representative of two independent experiments with similar results. Statistical significance was defined as follows: (*p,0.05;
** p,0.005) (Student’s t test & Mann-Whitney U test).
doi:10.1371/journal.pone.0016667.g001
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3 STMDhfq and boosted twice with the
same dose, the mice showed a significant reduction (P=0.0079) in
the bacterial load upon challenge compared to the organs of the
control unprimed mice (Figure 3A). However, all the vaccinated
mice did succumb to death upon challenge with the STM-WT like
the placebo control mice within 10 days (Figure 3B). We then
increased both the oral immunization and the booster doses to 10
4
and 10
5 CFU/mouse. In case of the mice primed with either 10
4 or
10
5 vaccine strain, there was a substantial decrease (P=0.0079) in
the bacterial burden and none of the vaccinated mice succumbed to
death upon challenge with STM-WT (Figure 3C & D).
Therefore, the hfq deletion mutant gives protection against
subsequent challenge with the virulent Salmonella strain.
Another important factor determining efficiency of the live
attenuated oral vaccine is the number of doses. So, we further
evaluated whether a single dose of the STMDhfq priming is
sufficient to give protection against challenge with virulent
Salmonella. A cohort of five mice were vaccinated with 10
8 CFU
of STMDhfq and challenged with 10
7 WT bacteria per mouse on
7
th day post vaccination. We observed that there was an average of
15-fold reduction (P=0.0079) in the organ load of mice with single
dose vaccination (Figure 4A). Moreover as shown in Figure 4B,
single dose of vaccination followed by challenge after 7 days with
the STM-WT (10
8) resulted in 100% survival whereas unvacci-
nated mice succumbed to death within two weeks. This data
strongly suggests that single dose of vaccination with the STMDhfq
can confer protection against the virulent Salmonella.
Long term immunological memory induction by the
STMDhfq vaccine strain
One of the problems with oral live attenuated vaccine has been
the lack of long-term immunological memory. Thus, we examined
the capacity of mice vaccinated with single dose (10
8) to mount a
recall response 52 days post vaccination (45 days after clearance).
Figure 2. STMDhfq mutant is highly safe for infection in murine model. (A & B) Survival curves. Mice were infected orally (A) at a dose of
10
8 or intraperitoneally (B) with a dose of 10
4 bacteria per mouse (n=10) and mice were observed twice daily for survival. (C) Reduced fecal shedding
of the STMDhfq. Mice were infected orally with the STM-WT or STMDhfq mutant strains at a dose of 10
7 bacteria/mouse. Uninfected mice were used
as control. Fresh fecal pellets were collected at the indicated time points and shedding was determined by plating on culture media. Data is
represented as the number of bacteria per gram weight of the fresh fecal pellets. Shown are the combined results from two experiments with 5 mice
in each group. Statistical significance was defined as follows: (*p,0.05) (Student’s t test & Fischer’s exact test).
doi:10.1371/journal.pone.0016667.g002
hfq and Vaccination
PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e16667Age matched unvaccinated challenged mice died within two weeks
after challenge whereas vaccinated challenged mice showed 100%
survival (Figure 4C). This data indicates that the STMDhfq is able
to induce long-term immunological memory.
STMDhfq vaccine strain is safe in pregnant mice
Pregnancy is a transient immuno-compromised condition and
leads to increased susceptibility to invading pathogens, resulting in
abortion and congenital defects in the fetus [32,33,34,35]. Thus,
the possibility of pregnancy failure after challenge with the
STMDhfq and WT in pregnant mice model was studied. Two
groups of ten mice were administered orally with STM-WT and
STMDhfq vaccine strain at 12–15 days of gestation (mid pregnancy
stage) with a dose of 10
8. Mice were scored for the delivery of pups
and their survival every day post infection. We found that the
STM-WT virulent strain caused the death of four mice and
induced abortion in three others. Only three mice delivered pups
normally; but 14 out of 16 pups died within 48 h after delivery.
On the other hand, out of 10 pregnant mice administered with the
STMDhfq mutant strain, one mouse died but remaining mice
delivered normal healthy pups and the pups remained healthy up
to 7 weeks (monitored for 7 weeks only, Table 1).
Oral vaccination with the STMDhfq increases the total
number of splenic CD4
+ T cells
To address the mechanism responsible for the protective
immunity conferred by the vaccine strain, we studied the status of
CD4
+ and CD8
+ T-lymphocyte population in the orally infected
mice (10
7). Total splenocytes were isolated from the naive mice and
mice infected with either STM-WT or STMDhfq at various time
points (4
th and 7
th day post infection) and stained with anti-CD4
+ or
anti-CD8
+ specific antibodies. Although no significant difference
was observed in the CD4
+ T-lymphocyte population in the
vaccinated mice at 4
th day post infection, there was a<6% increase
(P=0.003) in the same at 7
th day post infection when compared to
that in the STM-WT infected mice (Figure 5A & B).
Next, we determined whether the oral vaccination with
STMDhfq (10
8) affects the status of CD4
+ and CD8
+ T-lymphocyte
population with or without WT challenge (10
7). Total splenocytes
were isolated from naive and vaccinated mice (at 7
th day post
Figure 3. Multiple immunizations with STMDhfq confer protection against virulent Salmonella. Groups of 5 mice were immunized orally
with 10
3 (A&C), 10
4 or 10
5 (B&D) STMDhfq for two booster doses followed by challenge with WT through oral route (for organ load: 10
7 and for
survival analysis: 10
8 of WT) 7 days after the final booster dose. Control mice received PBS. 7 days after challenge, mice were sacrificed and bacterial
load in different organs was enumerated using direct cultures of serially diluted homogenized samples. A&B depict bacterial load in different organs
and C&D shows survival curves. Result presented is one of two independent experiments performed. Statistical significance was defined as follows
*p ,0.05; ** p,0.005 (Mann-Whitney U test & Fischer’s exact test).
doi:10.1371/journal.pone.0016667.g003
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challenged mice (at 7
th day post challenge). The mice vaccinated
with the STMDhfq showed significant increase (P=0.0129) in the
helper T cell population compared to that in the unvaccinated
mice. The level of helper T cells was considerably higher in the
vaccinated-challenged mice in comparison to that in the PBS-
challenged ones (P=0.012) (Figure 6A &B). However, there was
no change in the number of CD8
+ T cells in both the cases (Figure
S3&S4). Interestingly, we observed that the numbers of CD4
+ T
cells were slightly reduced with the STM-WT infection. Thus our
results suggest that vaccination induces CD4
+ T-cell population
and maintains the same even after infection, without altering the
CD8
+ T-lymphocyte levels.
Vaccination with the STMDhfq increases the serum IFN-c
and IL-6 levels
Cytokine profile of the serum after vaccination indicates the
kind of immune response elicited. Th1 cytokines (IFN-c, IL-2 and
Figure 4. Single dose of vaccination imparts protection against WT Salmonella and induces long-term immunological memory. BALB/
c mice were vaccinated through oral route with 10
8 CFU of STMDhfq or PBS and challenged with either 10
7 CFU of WT for assessing organ load (A) or
10
8 of WT for assessing mortality (B). 7 days after challenge, mice were sacrificed and bacterial load was enumerated. For long-term immunological
memory mice were challenged orally after 52 days of vaccination (C). Each group contains 5-6 mice. Statistical significance was defined as follows
*p ,0.05 (Mann-Whitney U test & Fischer’s exact test).
doi:10.1371/journal.pone.0016667.g004
Table 1. Safety of the STMDhfq vaccine strain in pregnant mice.
No. of pregnant
mice
Relevant
genotype
No. mice died before
delivery (healthy/dead) No. of abortions
Death of pups after delivery
(no. of death/total no.)
10 STM-WT 6/4 3 14/16
10 STMDhfq 9/1 0 0/32
Pregnant BALB/c mice (12–15 days of gestation) were infected orally at a dose of 10
8 bacteria per mouse with the STM-WT or the vaccine strain STMDhfq and observed
for abortion and the offspring outcome.
doi:10.1371/journal.pone.0016667.t001
hfq and Vaccination
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16667TNF-a) are important for cell mediated immunity, while the Th2
cytokines (IL-4, IL-6 and IL-10) are important for increased
antibody production [36]. Serum levels of IFN-c and IL-6 in
vaccinated (10
8) and PBS administered mice, with or without
challenge (10
7) were estimated. Vaccinated mice had higher serum
IFN-c and IL-6 than the PBS administered mice (P=0.0029) The
serum IL-6 and IFN-c levels of vaccinated mice further increased
upon challenge while remaining lower than that of unvaccinated
challenged mice (Figure 7A & B). In summary, our data suggests
that the oral vaccination with the STMDhfq increases the IFN-c
and IL-6 levels in the serum and might help the host indirectly to
reduce the count of virulent Salmonella.
Vaccination with STMDhfq markedly elicits the humoral
immune response
Protection against Salmonella is mediated through mucosal and
serum antibodies (Secretory IgA and serum IgG) as well as cell
mediated immunity [37]. The increase in secretory IgA as well as
serum IgG antibodies are surrogate markers of protection
conferred by an efficient oral vaccine candidate [38]. In order to
check whether vaccination with the STMDhfq increased antibody
titers, we measured mucosal as well as serum antibody levels in the
vaccinated (10
8) versus control mice with and without challenge
(10
7). We determined the antibody levels against two surface
antigens of the Salmonella, namely LPS (Figure 8A & B) and outer
membrane proteins (OMPs) (Figure 8C & D). Mucosal IgA and
serum IgG levels markedly increased in vaccinated mice compared
to naive mice (P,0.05). The antibody titers remained high in case
of mice vaccinated and challenged compared with the unvacci-
nated and challenged mice (P,0.05). The elicited humoral
immune response remained 4 weeks after immunization with
mutant strain (Figure S5). It is evident from our results that
STMDhfq induces an effective humoral immune response.
STMDhfq is presented better than the STM-WT in an in
vitro antigen presentation assay
Hopkins et al. in a previous study had reported that the
dendritic cells internalize Salmonella early after oro-gastric inocu-
lation of mice or injection in a ligated loop of intestine [39].
Dendritic cells are principle components of the innate immune
system which are able to prime adaptive immune response by
acting as antigen presenting cells [40]. Dendritic cells capture or
sample antigens in the peripheral tissue, transport antigens to the
lymph nodes and present the processed antigens to T cells via the
major histocompatibility complex (MHC) molecules [41]. Thus in
order to understand the immunogenicity of the STMDhfq vaccine
strain we compared the stimulation of T cell proliferation by bone
marrow-derived dendritic cells (BM-DC) which are infected with
equal number of STM-WT or STMDhfq in an in vitro T cell
proliferation assay (number of viable cells are same upon infection
with WT and mutant). STMDhfq infected DCs stimulated the T
cell proliferation to considerably (P=,0.005) higher levels than
the STM-WT infected DCs. The lymphocyte proliferation is
further enhanced with increased ratio of DC to T cells (Figure 9).
Further the viability of DCs infected with WT or STMDhfq
remains unchanged (Data not shown). This clearly demonstrates
that the vaccine strain STMDhfq is presented better than the
STM-WT.
Discussion
In this study, we evaluated the efficacy of the highly attenuated
STMDhfq mutant to serve as a live vaccine against salmonellosis in
the murine typhoid model. We have constructed hfq deficient strain
of S. Typhimurium and investigated the virulence of this strain. The
deletion mutant was compromised in its intracellular proliferation
capacity and was also severely attenuated in vivo following oral
Figure 5. Flow cytometric analysis of CD4
+ T cell population in the spleen on 4
th day (A) and 7
th day (B) post infection. Group of mice
were inoculated with the STM-WT or STMDhfq with dose of 10
7 bacteria per mouse. Uninfected mice were used as control. Splenocytes were isolated
on 4
th and 7
th day post infection from both infected and control mice and stained with FITC-conjugated anti-CD4 MAb. The relative levels of CD4
+ T-
lymphocytes were measured through FACS. Data was analyzed with BD Cell-Quest software and represented by dot plot. The results are
representative of two independent experiments. Each group consisted of 4-5 mice. Statistical significance was defined as follows: (* p,0.05)
(Student’s t test).
doi:10.1371/journal.pone.0016667.g005
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restored virulence in the mutant. These results are in accordance
with the work of Sittka et al. [28] where they reported that the S.
Typhimurium hfq mutant was attenuated in competition with the
parental strain in an intraperitoneal infection of BALB/c mice and
that the bacterial recovery was also low after oral infection.
Figure 6. Analysis of splenic CD4
+ T cell population in vaccinated and unvaccinated mice with or without challenge. Group of mice
were orally given PBS or 10
8 STM Dhfq bacteria and then challenged with 10
7 CFU of the STM-WT per mouse. On 7
th day post vaccination and 7
th day
post challenge, single cell suspension of splenocytes were prepared and stained with FITC-conjugated anti-CD4 MAb. The relative levels of CD4
+ T-
lymphocytes were measured through FACS. Data was analysed by BD Cell-Quest software and represented through dot plot (A) and bar graph (B).
Statistical significance was defined as follows: (* p,0.05) (Student’s t test). Each group consisted of 4-5 mice.
doi:10.1371/journal.pone.0016667.g006
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all Salmonella genes indicating that Hfq acts as a true global
regulator in Salmonella [42]. Hfq predominantly affects the
expression of two type three secretion systems (T3SS) encoded
by Salmonella pathogenicity islands (SPI), namely SPI-1 and SPI-2.
Salmonella uses these type three secretion systems (T3SS) to deliver
effectors into host cells thereby facilitating host invasion and
intracellular survival [27,28,42]. The genes regulated by Hfq also
include many LPS biosynthesis related genes and ABC transport-
ers [43,44] which are very important in imparting resistance to
antimicrobial peptides. Hfq also regulates iron uptake and storage
in bacteria through small RNAs. The available literature shows
Hfq’s multi-functional role in Salmonella biology. Therefore, the hfq
deletion mutant was evaluated for its efficacy as a potential vaccine
strain.
Our data clearly suggests that the STMDhfq mutant is an
effective oral vaccine candidate in the murine model and can be
given both in booster as well as in single dose. Vaccination with
subsequent challenge reduced the bacterial burden significantly as
compared to the unvaccinated mice. Moreover, the bacterial load
was completely cleared within 3 weeks post challenge in
vaccinated mice (data not shown). Lower vaccine dose (10
3, given
twice in boosters) however, was incapable of rescuing the mice
from a lethal WT challenge due to insufficient priming. Hence
when the immunization dose was raised to 10
4 or 10
5, the mice
showed 100% survival. Furthermore, the STMDhfq also conferred
long term protection against challenge. This suggests that the
vaccine strain is probably effective in inducing a specific adaptive
immune response, resulting in long term protection against
Salmonella infection.
One of the major pitfalls of live attenuated oral vaccine strains is
environmental contamination through fecal matter, which in turn
is associated with health and safety concerns. Studies with human
volunteer trials of different Salmonella Typhimurium vaccine strains
showed greater shedding of the vaccine strains in the feces
[45,46,47]. The degree of shedding of viable Salmonella after oral
inoculation varies substantially between different Salmonella
serovars. Salmonella Typhimurium vaccine strains show markedly
higher intestinal colonization and excretion for longer duration
than the same Salmonella Typhi vaccine strains [48]. The reduced
fecal shedding of STMDhfq is an added advantage with respect to
its impact on the environment.
An interesting observation was unlike the STM-WT, STMDhfq
infection did not induce abortion in pregnant mice and the newly
delivered pups remained healthy for several weeks. This
observation hints at the safety of the usage of the vaccine strain
in pregnant mice. Only subunit, killed or toxoid vaccines have
been used so far to vaccinate pregnant animals instead of live
attenuated vaccines due to the possibility of transmission of disease
to the fetus. Moreover, these vaccines do not elicit any mucosal
immunity. Abortions in pregnant animals in live stock due to
Salmonella serovars cause immense economic losses [33]. Thus the
use of hfq deletion mutant to vaccinate live stock can be
considered.
To investigate the basis of protective immunity imparted by the
STMDhfq, we examined the splenic T cell population. There was
an increase in the total splenic CD4
+ cells in STMDhfq infected
mice compared to the naive as well as the STM-WT infected mice
7 days post infection. CD4
+ T cells have profound effect on
protective immunity as they assist the B-cells to produce more
antibodies and in the generation of Salmonella specific CD8
+ T cells
[49,50].We also observed that the numbers of CD4
+ T cells were
slightly reduced with the STM-WT infection. The reduction in the
number of T cells by virulent Salmonella Typhimurium could be
due to induction of apoptosis in a SPI-2 dependent manner by live
bacteria [40,51]. This may not be the case with the STMDhfq as
SPI-2 encoded type three secretion system is down regulated
[27,28,42]. In our study we did not observe any increase in the
number of CD8
+ T cells in an early stage of infection since
Salmonella delays substantially the CD8
+ T cell response until the
second week of infection [52]. Further studies are needed in an in
vivo model of Salmonella antigen presentation to ascertain the nature
and specificity of the increased T cells.
It has been confirmed that the Th1 response (IFN-c and TNF-
a) is essential in inhibiting the systemic spread of Salmonella during
initial stages of infection. However, infection with certain
attenuated Salmonella strains can induce Th2 response [37,53].
IFN-c production by large number of Salmonella specific T cells
and NK cells is at least in part responsible for the increased
immunity against secondary infections. The levels of IFN-c and
IL-6 have been reported to be directly proportional to the severity
Figure 7. Analysis of serum cytokine levels with single dose of
vaccination. (A) IFN-c (B) IL-6. Group of mice were orally given PBS or
STMDhfq (10
8) and then challenged with STM-WT (10
7 CFU/mouse) at
7
th post vaccination. Serum was collected on 7
th day post vaccination
(from unchallenged mice) and 7
th day post challenge (from challenged
mice) and cytokine levels were measured using ELISA. Data is
representative of two independent experiments (n=4-5). Statistical
significance was defined as follows: (*p,0.05; ** p,0.005) (Student’s t
test).
doi:10.1371/journal.pone.0016667.g007
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our findings where we observed decrease in the level of IFN-c and
IL-6 in vaccinated and challenged mice. Nonetheless, the observed
level could effectively clear the WT. The WT infected mice
showed higher cytokine levels which could be attributed to the
high virulence and burden of the wild type strain[55,56], whereas
vaccination with subsequent challenge showed lower cytokine
levels, which could possibly be due to lower WT load on organs
after vaccination [35,56]. Apparently, an optimal cytokine level,
which is neither as high as that in WT infected condition nor as
low as that in the vaccinated alone, is sufficient to confer protective
immunity.
Infection of B-cell deficient animals with attenuated Salmonella
indicated the contribution of antibody mediated immune respons-
es in protection against Salmonella infection [57]. In humans, high
Salmonella Typhi Vi antigen specific antibodies correlate with the
protection against infection. These two findings suggest that
humoral immune response is important in effective clearance of
primary Salmonella infection. In addition to LPS specific antibodies,
OMP specific antibodies also contribute to the acquired resistance
to Salmonella infection though to a lesser extent. Immunization of
mice with purified OMPs can protect the mice from subsequent
Salmonella infections and induces sustained lifelong memory
responses without any added adjuvant [58,59]. Cristina Gil-cruz
et al. showed that antibodies to OmpD alone can reduce non-
typhoidal Salmonella infection [60]. Moreover porins can act as
activators of both innate and adaptive immune system. Absence of
hfq leads to the chronic activation of the RpoE mediated envelope
stress response and also markedly increases the OmpD levels [28].
In the present study, we observed that vaccination with STMDhfq
increases the LPS and OMP specific IgG antibodies in the serum
as well as S-IgA in the intestinal washes. As shown by Michetti et
al., it can be inferred that the induced S-IgA would presumably
block the entry of Salmonella at the mucosal surface possibly by
immune exclusion [61]. Increased serum IgG can enhance the Fc-
receptor and complement receptor mediated uptake of Salmonella
by the phagocytic cells and bacterial clearance from blood by
opsonization.
STMDhfq induced protective immunity can also be explained by
enhanced antigen presentation of hfq deletion mutant by DCs.
Cheminay et al. reported that virulent Salmonella inhibits the
MHC-II dependent antigen presentation by dendritic cells and
Figure 8. Humoral immune response elicited by single dose of vaccination with STMDhfq. Group of mice were orally given PBS or
STMDhfq (10
8) and then challenged with STM-WT (10
7 CFU/mouse) at day 7 of post vaccination. Serum and intestinal mucus were collected on 7
th
day post vaccination (from unchallenged mice) and 7
th day post challenge (from challenged mice). Serum IgG (B&D) and intestinal S-IgA (A&C)
antibodies specific for LPS and OMP were measured by ELISA. The samples were assayed in triplicate and the antibody titer is expressed as the
absorbance at 450 nm. Data is representative of two independent experiments. Statistical significance was defined as follows: (*p,0.05; ** p,0.005)
(Student’s t test). (n=4-5).
doi:10.1371/journal.pone.0016667.g008
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capacity to inhibit the antigen presentation depends on the ability
of the pathogen to alter the trafficking or maturation of the
Salmonella containing vacuole (SCV) inside the DC which in turn
depends on the presence of functional SPI-2 and production of
nitric oxide (NO) [40]. The reason for increased presentation of
STMDhfq vaccine strain could be due to lack of functional SPI-2
[27,28,42] or decreased production of nitric oxide (NO).
Hfq is required for the efficient translation of both stationary-
phase sigma factor RpoS (s
S) and envelope stress response sigma
factor RpoE (sE) [62]. Coynault et al. reported that the rpoS
mutants are impaired in their capacity to colonize Peyer’s patches
after oral infection and are able to protect susceptible BALB/c
mice against subsequent oral challenge with virulent STM-WT
strain [16]. Vaccines with reduced ability to persist in vivo along
with good immunogenicity are suitable for a human vaccine where
side effects of vaccination are major concern. While our work was
in progress, Karasova et al. reported that the S. Enteritidis hfq
deletion mutant was susceptible to the components of the innate
immune system such as serum and polymyxin B [63].
In summary, our present work demonstrates that Salmonella
Typhimurium hfq deletion mutant can be a live attenuated
vaccine, when given orally in a single dose can induce protective
immune response upon subsequent challenge with virulent
Salmonella. Not all attenuated Salmonellae strains can be presented
well and this has been a stumbling block in the generation of a
successful vaccine against Salmonella. Vaccination with hfq deletion
mutant results in the active and specific protective immunity. Our
work strongly suggests that the hfq deletion mutant can be
considered for vaccination of humans and economically important
livestock. Also the potential use of hfq deletion mutant as a
heterologous antigen delivery system appears to be a very
attractive option which still remains unexplored.
Materials and Methods
Ethics Statement
All the work with animals has been done with Institution
approved ethics protocol by the Center for Animal facility Ethics
Committee. The ethics number being CAF/ETHICS/189/2010.
The ethics committee consisted of Institutional Animal ethics
committee comprising of Animal facility Chairman, Convener and
Scientists.
Bacterial strains and growth conditions
Salmonella Typhimurium 14028 used in this study as the wild
type parental strain was a kind gift from Prof. Michael Hensel
(Max von Pettenkofer-Institute for Hygiene and Medizinische
Mikrobiologie, Germany). The Dhfq deletion mutant was con-
structed in the parental wild type strain. Bacteria were grown at
37uC in Luria Broth (LB) in the presence of carbencillin (50 mg/
ml) or kanamycin (50 mg/ml) as and when required for the
selection of the different strains.
Eukaryotic cell lines and growth conditions
RAW 264.7 cells were a kind gift from Prof. Anjali Karande
(Department of Biochemistry, Indian Institute of Science, India).
INT-407, HT-29, HEK-293 and CaCo-2 cells were obtained from
National Center for Cell Science (NCCS), Pune, India. All the cell
lines were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma), supplemented with 10% fetal calf serum (Sigma).
For growth of CaCo-2 cells, DMEM was further supplemented
with 1X non- essential amino acid solution. All the cells were
maintained at 37uC in 5% carbon dioxide.
Generation of the hfq deletion mutant in Salmonella
Typhimurium
The hfq mutant was generated by one step gene inactivation
strategy as described by Dastenko and Wanner [30]. Briefly, the
STM 14028 strain was transformed with pKD46 carrying lambda
red recombinase system under the arabinose inducible promoter.
The transformants carrying the helper plasmid pKD46 were grown
in LB with ampicillin (50 mg/ml) and 10 mM L-arabinose (Sigma)
till the OD reached 0.38–0.4 at 600 nm. Electro-competent cells
were prepared by washing the cells thrice with ice cold MilliQ water
and 10% glycerol. PCR products containing the kanamycin-
resistance gene (from pKD4) flanked by sequences upstream and
downstream of the hfq gene was amplified with primers (HK1and
HK2) and electroporated into the STM 14028 strain carrying
pKD46. Electroporation was done according to the manufacturer’s
instructions (Bio-Rad). Mutant was selected for its ability to grow on
LB containing kanamycin and the same was confirmed by
confirmatory primers (HC1 and HC2) designed against the flanking
loci of the hfq gene and internal primers (HI) designed against the
kanamycin cassette sequence. In the STM-WT strain, a 310 bp
band was amplified whereas in the STMDhfq strain, 1.5 Kb band
(corresponding to Kanamycin cassette) was amplified. The deletion
mutant thus generated was named STMDhfq.
Sequences of the primers used in this study are as follows:
HK1: 59atggctaaggggcaatctttacaagatccgttcctggtgtaggctggagctgcttcg 39
HK2: 59ttattcagtctcttcgctgtcctgttgcgcagtagcatatgaatatcctcctta 39
HC1: 59gcatataaggaaaagaga39
HC2: 59gataaacagcgcgtgaac39
HI: 59cagaccgttcagctggat39 (used as reverse primer)
Figure 9. Increased antigen presentation of the STMDhfq by
Denditic cells. Dendritic cells were isolated from the BALB/C mice and
were plated at 5610
4 cells/well in 96 well flat-bottomed tissue culture
plates. C57BL/6 mice were infected with STM-WT for pre stimulation
and T-lymphocytes were isolated on 5
th day aseptically. DCs were
infected with the STM-WT and STMDhfq. The infected DCs were then
co-cultured with T-lymphocytes at a ratio of (1:1) and (1:10) for 72 h and
then pulsed for 16 h with [
3H] thymidine (1 mCi/well). The incorporation
of [
3H] thymidine in proliferating T cells were measured by liquid
scintillation counter. T cell proliferation was represented counts/min
using a beta-counter. The results are representative of two independent
experiments in triplcate. Statistical significance was defined as follows:
(*p,0.05) (Student’s t test).
doi:10.1371/journal.pone.0016667.g009
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Genomic DNA isolated from Salmonella Typhimurium 14028 strain
was used as template to amplify the hfq gene using the gene specific
primers (Forward: 59taggatccatggctaagg39 and Reverse: 59cgcaagcttt-
tattcagt39). The amplified product was purified and insert along with
the purified vector pQE60 were digested with BamHI and Hind III.
The digested vector and insert were ligated and transformed into E.
coli DH5acompetent cells and plated onto LA-carbencillin plates. The
colonies were screened for plasmids having the appropriate insert by
restriction digestion. The purified plasmid containing hfq gene was
then transformed into STMDhfq electro-competent cells. The resulting
strain was named as pQE60hfq strain.
Intracellular proliferation assay
Different cell lines such as RAW 264.7, INT-407, HT-29 and
CaCo-2 at a concentration of 1610
5 to 2610
5 per well were
seeded in 24-well plates 12 h prior to infection. For the infection of
RAW 264.7 cells, S. Typhimurium strains were grown till
stationary phase in LB with the appropriate antibiotic. For
infection of epithelial cells, stationary-phase cultures were diluted
1: 33 in LB and grown for 3 h (late-exponential phase) prior to
infection to induce SPI-1 encoded genes required for invasion of
non-phagocytic cells. The OD600 of the cultures was adjusted to
0.3 and the resulting bacterial suspensions were used to infect the
cells at a multiplicity of infection (MOI) of about 10. The plates
were centrifuged at 1000 rpm for 10 min and incubated at 37uC
for 25 min. The cells were then washed with PBS to remove excess
bacteria and fresh medium containing 100 mg/ml gentamicin was
added. After 1 h, the medium was discarded followed by three
PBS washes, and then medium containing 25 mg/ml gentamicin
was added and incubated for further time periods. After specified
incubation periods, cells were lysed with 0.1% Triton X-100
(Sigma) and were plated at different dilutions on LB agar
containing appropriate antibiotic. The fold intracellular replica-
tion was calculated by dividing the intracellular bacterial load at
16 h by the intracellular bacterial load at 2 h.
Animal infection
Six to eight weeks old BALB/c mice were issued from Central
Animal Facility, Indian Institute of Science, Bangalore, India and
maintained under specific pathogen free conditions. The bacterial
strains were grown overnight at 37uC under shaking condition
(180 rpm). Cells were centrifuged, washed, resuspended in sterile
PBS and administered to mice at the indicated doses. Comparative
analysis of the wild type versus vaccine strain burden in different
organs was done by infecting mice orally with a dose of 10
7
bacteria/mouse. After 4
th and 7
th day, mice were sacrificed
followed by the isolation of liver, spleen and mesenteric lymph
nodes. The organs were weighed and homogenized in 1ml PBS.
The bacterial load in the organs was determined by plating serial
dilutions of the homogenate on LB agar plates with selective
antibiotic. The CFU was calculated per gram weight of the organ.
Also, the total splenocytes were isolated for analyzing the CD4
+
and CD8
+ T-lymphocyte population.
Safety of the vaccine strain
Safety of the vaccine strain in mouse model was determined by
infecting the mice with a dose of 10
8 bacteria/mouse (orally) and
10
4 bacteria/mouse (intraperitoneally). The safety of the vaccine
strain was analyzed in comparison with that of the wild type strain
by observingthe micetwice daily for mortalityand morbidity. Same
was tested in the pregnant mice which were infected (10
8 bacteria/
mouse) orally at mid pregnancy stage (12–14 days of gestation).
Fecal shedding of the STM-WT and STMDhfq mutant
Cohorts of five mice each were orally inoculated either with
STM-WT or STMDhfq mutant with a dose of 10
7 bacteria. Fresh
fecal pellets were collected after every 12 h till 4
th day and every
24 h from 4
th day onwards. To avoid drying of fecal pellets, mice
were reared in cages with Whatmann papers. Freshly recovered
fecal pellets were weighed and suspended in 1 ml of PBS. Samples
were centrifuged at 1500 rpm for 10 min and plated onto plates
with selective antibiotics. Data is represented after normalizing the
CFU per gram weight of the fresh fecal pellets.
LD50 determination
Six to Eight week old female BALB/c mice were fasted
overnight prior to inoculation. To determine LD50 values, groups
of ten animals were orally infected with specific inoculum for each
strain. Animal deaths were recorded up to 3 weeks.
Immunization of mice with STMDhfq mutant strain
Multiple booster dose immunization. Cohorts of five mice
were orally primed with the STMDhfq mutant strain with a dose of
10
3,1 0
4 or 10
5 bacteria/mouse followed by two booster doses on
7
th and 14
th day. Control mice received PBS (Figure S2). All the
subsequent steps (challenge, sacrifice) were carried out with a gap
of seven days between them. After 7 days of second booster dose,
the mice were challenged with 10
7 STM-WT through oral route
for analyzing organ infiltration. For survival assay, mice were
challenged with 10
8 CFU/mouse through oral route.
Single dose immunization. Mice were vaccinated with a
single dose of STMDhfq (10
8) and subsequently challenged with
10
7 STM-WT on 7
th day of post vaccination. Mice were sacrificed
7 days post challenge and bacterial load in liver, spleen and
mesenteric lymph nodes were determined as described above. For
survival assay, mice were challenged through oral route with
10
8 CFU of WT per mouse.
Long term immunological memory induction by the
STMDhfq vaccine strain
Cohort of five mice was vaccinated orally with a single dose of
10
8 STMDhfq vaccine strain. After 52 days of post vaccination
mice were challenged orally with 10
8 STM-WT per mouse. To the
control mice, PBS was administered. After challenging, vaccinated
and non vaccinated mice were examined daily for morbidity and
mortality.
Analysis of serum cytokine levels
Blood was collected through cardiac puncture from the single
dose immunized mice with or without challenge. Serum was
separated and IFN-c and IL-6 cytokine levels were assayed by
ELISA (e-Bioscience) as per the manufacturer’s protocol.
Preparation of intestinal mucus
Mice were starved for 12 h before collecting intestinal mucus.
Mice were scarified and intestinal region was collected and cut into
small pieces. One PBS flush was given to remove fecal matter and
intestine was reversed and mucus was collected by scrapping with
forceps. The collected mucus was centrifuged at 12000 rpm and
the collected supernatant was used for estimation of secretary IgA.
Outer Membrane Protein Isolation (OMP)
Isolation of OMPs was carried out by a method of Hamid et al.
[64]. Briefly, over-night grown bacterial culture was centrifuged
and the pellet was washed thrice with 10 mM Tris-HCl (pH 7.5),
and pellet equivalent to 1.0 g wet weight of bacteria was extracted
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10 mM EDTA, and 6 M urea) for 1 h at 4uC. The bacterial
extract was dialyzed against MilliQ water for 3 days with frequent
changes. The dialyzed material was centrifuged at 6000 rpm for
1 h. The supernatant containing surface proteins was collected
and crude OMP sample was passed through a polymyxin B-
agarose column (Sigma) to remove the contaminant endotoxin.
Endotoxin levels in purified protein preparations was analysed
using the E-Toxate kit (Sigma). The purified OMP sample was
lyophilized and was stored at 220uC. The protein content in the
samples was measured by Bradford method of protein estimation.
Estimation of IgG and IgA antibodies from serum and
intestinal mucus
LPS and OMP specific IgG and IgA antibodies in serum and
intestinal mucus were assayed by ELISA. Purified LPS from
Salmonella Typhimurium was obtained from Sigma-Aldrich where
as OMPs were isolated as described below. Briefly, Nunc ELISA
plate was coated with 100 ng/well of LPS or 500 ng/well of OMP
in 100 ml of 0.02% Trichloro acetic acid (TCA). After 1 h
incubation at 37uC, LPS or OMP coated wells were washed with
wash buffer (0.5% PBS-Tween-20) and blocked with 3% BSA in
the same. After 1 h incubation, wells were washed and incubated
with dilutions of serum in wash buffer (1:10) for 1 h at 37uC. Then
wells were washed and 100 ml of anti-IgG and anti-IgA antibodies
(Sigma) which are conjugated to HRP were added (1:10,000
dilutions) followed by incubation at 37uC for 1 h and addition of
100 ml of substrate solution subsequently. After 15 min incubation,
50 ml of stop solution was added to each well and OD was
measured at 450 nm. In case of intestinal mucus, equal amount of
protein was taken after estimation by Bradford’s method.
Flow-cytometric analysis of T cell population
Splenocytes were isolated aseptically from and single-cell
suspensions were obtained by crushing them between rough
surface glass slides followed by erythrocyte lysis using RBC lysis
buffer (0.1M NH4Cl, 1 mM KHCO3, 1 mM EDTA in H2O).
Cells were stained separately with FITC-conjugated anti-CD4 (e-
Biosciences) MAb, or PE-conjugated anti-CD8 (e-Biosciences)
MAb. After 1 h incubation at RT, cells were washed with PBS and
one million (10
6) cells were taken for flow-cytometric analysis (BD
FACS Canto-II). Data was analyzed with FACS Diva and Cell
Quest Pro software (Becton Dickinson, Mountain View, Calif.).
Purification of T lymphocytes
Five days of post infection of allogenic C57BL/6 mice with
STM-WT, splenocytes were prepared by incubating small pieces
of spleen in serum-free, calcium-free HBSS at 37uC for 45 min.
This preparation was disaggregated by gentle pipetting to produce
a single-cell suspension. The cells were then washed in HBSS, and
erythrocytes were lysed with 1X RBC lysis buffer. Preparations
were filtered to remove debris and were resuspended in RPMI
with 10% FCS. Cells were incubated overnight to allow
macrophages to adhere. Non adherent cells were transferred to
fresh 30 mm dish which was coated with purified goat anti-mouse
IgG antibody (20 mg/ml) and incubated for 6 h. After 6 h of
incubation, non adherent cells were taken for assay. The purity of
the T cells was checked by FACS using mouse anti-CD3 antibody
conjugated to FITC (data not shown).
Preparation and culture of Dendritic cells
Murine bone marrow derived dendritic cells were prepared
from bone marrow of 6–8 week old naive BALB/c mice for
antigen presentation assay as described by Cheminay et al [40].
Briefly, femurs were cut off at the ends and the marrow was
flushed out. The cells were spun at 1,000 rpm for 10 min and
resuspended in RPMI containing 10 ng/ml GM-CSF (Peprotech),
10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin and cultured in 90 mm tissue
culture dish. Finally, after 5 days of culture the medium was
collected and the suspended cells were recovered and used for
purification using CD11c magnetic beads. Further, the cells were
found to be .90% CD11c
+ by fluorescence-activated cell sorting.
These cells were further checked for maturation markers like
CD80 and CD86 and it was found that the purified DCs were
immature (data not shown). The purified DCs were used for
further experiments.
In vitro antigen presentation assay
Modified method of Cheminay et al. was followed [40]. Briefly,
dendritic cells were isolated from BALB/c as described earlier and
were plated at a density of 5610
4 cells/well in 96-well flat-
bottomed tissue culture plates. Bacterial infection of the DCs was
performed as described in intracellular proliferation assay. Twelve
hours post infection, purified splenic T cells from allogenic
C57BL/6 mice were added to each well. DC and T cell ratio was
maintained at 1:10 and 1:1. Cells were co-cultured for 72 h and
then pulsed for 16 h with [
3H] thymidine (0.1 mCi/well). Cells
were harvested on glass fiber filters using a semi-automated cell
harvester (Nunc, Denmark). [
3H] thymidine was measured in a
liquid scintillation counter (Rack Beta) and T-cell proliferation was
plotted as mean counts/min of triplicate wells.
Statistics
In vitro data were analyzed by Student’s ‘‘t’’ test using Sigma
Plot. Mann Whitney U test were performed for mouse experiment
using commercially available software (Graph Pad Prism, San
Diego, CA). The mortality and survival data were analyzed using
Fishers exact test. Results were determined to be statistically
significant when a P value of less than 0.05 was obtained.
Supporting Information
Figure S1 Complementation of the STMDhfq strain with
pQE60hfq restores virulence. Intracellular replication of STM-
WT, STMDhfq and complemented strain in INT-407 (A) and
RAW 264.7 (B) cell line. INT-407 and RAW 264.7 cell lines were
infected with a MOI of 10 and lysed at 2 h and 16 h post infection.
Bacterial fold replication was calculated from 2 to 16 h as shown in
the graph. (C) Organ loads of STM-WT, STMDhfq and
complemented strain. Three groups of mice (6 each) were infected
with 10
7 CFU/mouse orally with each strain separately and
sacrificed on 4
th day of post infection. Bacterial counts in spleen,
MLN and liver were measured by plating on respective antibiotic
plates and were shown as CFU/gm.wt with standard errors.
Graphs are representative of two independent experiments with
similar results. Statistical significance was defined as follows:
(*p,0.05; **p,0.005) (Student’s t test & Mann-Whitney U test).
(TIF)
Figure S2 Immunization strategy followed to evaluate the
vaccine potential of the STMDhfq deletion mutant (A) multiple
immunization strategy; mice were primed with vaccine strain
followed by two booster doses on 7
th and 14
th day and then
challenged with virulent Salmonella strain on 7
th day after last
booster dose. (B) Single dose of vaccination: mice were vaccinated
and then challenged with virulent Salmonella strain after 7 days of
hfq and Vaccination
PLoS ONE | www.plosone.org 13 February 2011 | Volume 6 | Issue 2 | e16667post vaccination. For CFU analysis mice were challenged with 10
7
and for survival assay 10
8 CFU of WT.
(TIF)
Figure S3 Flow cytometric analysis of CD8
+ T cell population
in the spleen on 4
th day and 7
th day of post infection. Groups of
mice were inoculated with the STM-WT or STMDhfq with dose
of 10
7 bacteria per mouse. Uninfected mice were used as control.
Splenocytes were isolated on 4
th and 7
th day of post infection
from both infected and control mice and stained with PE-
conjugated anti-CD8 MAb. The relative levels of CD8
+ T-
lymphocytes were measured through FACS. Data was analyzed
with BD Cell-Quest software and represented by dot plots. The
results are representative of two independent experiments. Each
group consisted of 4-5 mice.
(TIF)
Figure S4 Flow cytometric analysis of splenic CD8
+ T cell
population in vaccinated and unvaccinated mice with or without
challenge. Group of mice were orally given PBS or 10
8 STM Dhfq
and then challenged after seven days of post vaccination with
10
7 CFU of STM-WT per mouse. On 7
th day post vaccination
(from unchallenged mice) and 7
th day post challenge (from
challenged mice) spleen were isolated and single cell suspension of
splenocytes were prepared followed by staining with FITC-
conjugated anti-CD8 MAb. The relative levels of CD8
+ T-
lymphocytes were measured through FACS. Data was analysed by
BD Cell-Quest software and represented through dot plot. Each
group consisted of 4-5 mice.
(TIF)
Figure S5 Estimationof the serum IgG and intestinal S-IgA levels
4 weeks after single dose of vaccination. Group of mice were orally
given PBS or vaccine strain (10
8), serum and intestinal mucus were
collected 4 weeks post vaccination. Serum IgG (B&D) and intestinal
S-IgA (A&C) antibodies specific for LPS and OMP were measured
by ELISA. The samples were assayed in triplicate and the antibody
titer is expressed as the absorbance at 450 nm. Result presented is
one of two independent experiments. Statistical significance was
defined as follows: (*p,0.05; **p,0.005)(Student’st test). (n=5-6).
(TIF)
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